MSI2 Knockdown Represses Extrahepatic Cholangiocarcinoma Growth and Invasion by Inhibiting Epithelial-mesenchymal Transition

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Jul 24

PMID 30034243

Citations 5

Authors

Feihu Hu

Chenhai Liu

Fang Xie

Xiansheng Lin

Ji Yang

Chao Wang

Qiang Huang

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the expression and functional role of Musashi2 (MSI2), an RNA-binding protein, in extrahepatic cholangiocarcinoma (eCCA).

Patients And Methods: We measured MSI2 expression in human specimens and cell lines using Western blot and quantitative real-time polymerase chain reaction, and we analyzed its association with clinicopathologic features in eCCA patients. Univariate and multivariate analyses were performed to identify risk factors correlated with overall survival and disease-free survival. Functional experiments were used to study the mechanisms of MSI2 in regulating eCCA cell growth, migration, and invasion.

Results: MSI2 expression was upregulated significantly in both human specimens and cell lines, and high MSI2 expression was associated with lymph node metastasis, advanced TNM stage, and poor prognosis in eCCA patients. Additionally, MSI2 overexpression promoted eCCA cell growth, migration, and invasion, while MSI2 knockdown repressed eCCA cell migration and invasion by inhibiting epithelial-mesenchymal transition.

Conclusion: MSI2 is an independent prognostic factor for eCCA patients, and MSI2 downregulation inhibits eCCA cell growth and metastasis. MSI2 may be a potential therapeutic target for eCCA patients.

Citing Articles

MicroRNAs and RNA-Binding Protein-Based Regulation of Bone Metastasis from Hepatobiliary Cancers and Potential Therapeutic Strategies.

Fagoonee S, Weiskirchen R Cells. 2024; 13(23).

PMID: 39682684 PMC: 11640337. DOI: 10.3390/cells13231935.

HuD regulates apoptosis in N2a cells by regulating Msi2 expression.

Gaikwad N, Sarwade R, Halder S, Agarwal G, Seshadri V PLoS One. 2024; 19(12):e0315535.

PMID: 39680531 PMC: 11649143. DOI: 10.1371/journal.pone.0315535.

MSI2 regulates NLK-mediated EMT and PI3K/AKT/mTOR pathway to promote pancreatic cancer progression.

Huang L, Sun J, Ma Y, Chen H, Tian C, Dong M Cancer Cell Int. 2024; 24(1):273.

PMID: 39097735 PMC: 11297748. DOI: 10.1186/s12935-024-03444-9.

[Advances in research of Musashi2 in solid tumors].

Yang Y, Zhao M, Ding T, Ni C, Zheng Q, Li X Nan Fang Yi Ke Da Xue Xue Bao. 2022; 42(3):448-456.

PMID: 35426812 PMC: 9010998. DOI: 10.12122/j.issn.1673-4254.2022.03.20.

Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling.

Sheng W, Shi X, Lin Y, Tang J, Jia C, Cao R J Exp Clin Cancer Res. 2020; 39(1):16.

PMID: 31952541 PMC: 6967093. DOI: 10.1186/s13046-020-1521-4.

References

Kudinov A, Deneka A, Nikonova A, Beck T, Ahn Y, Liu X . Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016; 113(25):6955-60. PMC: 4922167. DOI: 10.1073/pnas.1513616113. View

Techasen A, Namwat N, Loilome W, Duangkumpha K, Puapairoj A, Saya H . Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. J Hepatobiliary Pancreat Sci. 2014; 21(9):703-11. DOI: 10.1002/jhbp.125. View

Vaquero J, Guedj N, Claperon A, Nguyen Ho-Bouldoires T, Paradis V, Fouassier L . Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J Hepatol. 2016; 66(2):424-441. DOI: 10.1016/j.jhep.2016.09.010. View

Han Y, Ye A, Zhang Y, Cai Z, Wang W, Sun L . Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin. PLoS One. 2015; 10(8):e0136484. PMC: 4550418. DOI: 10.1371/journal.pone.0136484. View

Rosen C, Heimbach J, Gores G . Liver transplantation for cholangiocarcinoma. Transpl Int. 2010; 23(7):692-7. DOI: 10.1111/j.1432-2277.2010.01108.x. View

Puisieux A, Brabletz T, Caramel J . Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014; 16(6):488-94. DOI: 10.1038/ncb2976. View

Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T . E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011; 105(12):1885-93. PMC: 3251878. DOI: 10.1038/bjc.2011.452. View

Minuesa G, Antczak C, Shum D, Radu C, Bhinder B, Li Y . A 1536-well fluorescence polarization assay to screen for modulators of the MUSASHI family of RNA-binding proteins. Comb Chem High Throughput Screen. 2014; 17(7):596-609. PMC: 4135234. DOI: 10.2174/1386207317666140609122714. View

DeOliveira M, Cunningham S, Cameron J, Kamangar F, Winter J, Lillemoe K . Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; 245(5):755-62. PMC: 1877058. DOI: 10.1097/01.sla.0000251366.62632.d3. View

10.

Ilyas S, Gores G . Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145(6):1215-29. PMC: 3862291. DOI: 10.1053/j.gastro.2013.10.013. View

11.

Ito T, Kwon H, Zimdahl B, Congdon K, Blum J, Lento W . Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010; 466(7307):765-8. PMC: 2918284. DOI: 10.1038/nature09171. View

12.

Baulida J . Epithelial-to-mesenchymal transition transcription factors in cancer-associated fibroblasts. Mol Oncol. 2017; 11(7):847-859. PMC: 5496490. DOI: 10.1002/1878-0261.12080. View

13.

He L, Zhou X, Qu C, Hu L, Tang Y, Zhang Q . Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. J Cell Mol Med. 2013; 18(1):49-58. PMC: 3916117. DOI: 10.1111/jcmm.12158. View

14.

Marin J, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero M . Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1444-1453. DOI: 10.1016/j.bbadis.2017.06.005. View

15.

Huang D, Huang M, Lin X, Huang Q . CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco Targets Ther. 2017; 10:3817-3825. PMC: 5546808. DOI: 10.2147/OTT.S141476. View

16.

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

17.

Sirica A, Gores G . Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 2013; 59(6):2397-402. PMC: 3975806. DOI: 10.1002/hep.26762. View

18.

Kudinov A, Karanicolas J, Golemis E, Boumber Y . Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. Clin Cancer Res. 2017; 23(9):2143-2153. PMC: 5413399. DOI: 10.1158/1078-0432.CCR-16-2728. View

19.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

20.

Lee J, An S, Choi Y, Lee J, Ahn K, Lee J . Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells. Int J Oncol. 2016; 49(5):1945-1952. DOI: 10.3892/ijo.2016.3683. View